Online Inquiry
Cat.#: ASSD-221
| Description | Antifade Fluorescence Mounting Medium with DAPI (hardset) from Ace Therapeutics is used to prevent the photobleaching of fluorescent proteins and dyes during fluorescent imaging. This product contains DAPI which is a blue fluorescent DNA stain used to label cell nuclei. |
| Size | 10 mL |
| Applications | Cellular imaging, IHC(IF), ICC |
| Mounting | Aqueous (hardset) - cures in approximately 1 hour at RT |
| Antifade | Yes |
| Counterstain | DAPI |
| Refractive index | ≈1.45 (initial) which then increases to ≈1.518 once cured |
| Emission color | Blue |
| Excitation | 350 nm |
| Emission | 470 nm |
| Closest laser lines | 405 nm |
| Cell permeable | Yes |
| Storage | +4°C or -20°C long-term. |
| Shipping | Shipped at 4°C |
| Important | If the mounting medium solidifies prematurely during operation, simply heat the bottle to approximately 60°C and the mounting medium will reliquefy. We strongly recommend storing this product in a storage buffer containing 0.05% sodium azide and away from light. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-123 | Fluorescent β2 antagonist [(S)-propranolol-red] (AC123) | 500 μg | inquiry |
| ASSD-220 | Nitrofluorescein, Isomer 2 (AC220) | 1 g | inquiry |
| ASSD-198 | NHS-5(6)Carboxyrhodamine (AC198) | 25 mg | inquiry |
| ASSD-122 | Fluorescent β2 antagonist [(±)-propranolol] (AC122) | 500 μg | inquiry |
| ASSD-132 | Congo Red (AC132) | 100 mg, 1g | inquiry |
| ASSD-105 | Hoechst 33342 (AC105) | 10 mg, 100 mg | inquiry |
| ASSD-200 | Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) | 500 μg | inquiry |
| ASSD-169 | Calcium Ionophore A23187 (AC169) | 1mg, 5mg, 10 mg | inquiry |
| ASSD-218 | 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) | 25 mg | inquiry |
| ASSD-167 | Fura-2 AM (Cell permeant) (AC167) | 1 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.